Mirum Pharmaceuticals(MIRM)
Focus: Mirum is a publicly traded specialty pharma company focused on rare hepatic and cholestatic diseases using small molecule therapeutics. With $186M in FY2025 revenue, it operates at mid-cap biotech scale with deep expertise in bile acid disorders and liver disease.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
33+2 this month
Stable — net +2 jobs in 30d
17 added, 15 removed. Backfill posture.
Should You Work at Mirum Pharmaceuticals?
AI assessmentBest suited for specialists willing to build rare disease expertise in a resource-constrained but growing public company with clinical pipeline momentum.
Why Work Here
- Public company with $223M cash and positive revenue trajectory ($77M→$186M YoY growth) providing stability absent in pre-revenue biotech
- Focused specialty portfolio in rare/orphan hepatic diseases creates deep clinical expertise and reduced competition versus crowded therapeutic areas
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
1 imminent
CTEXLI
Hiring
Growing
Jobs increasing
Revenue
Key Products
$4M Part DStable
Peak
Established NDA generating majority of revenue; drives 53% of company sales but faces limited expansion potential in narrow patient population.
Help build intelligence for Mirum Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.